These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16267747)

  • 1. Listeria monocytogenes meningitis following imatinib mesylate-induced monocytopenia in a patient with chronic myeloid leukemia.
    Ferrand H; Tamburini J; Mouly S; Bouscary D; Bergmann JF
    Clin Infect Dis; 2005 Dec; 41(11):1684-5. PubMed ID: 16267747
    [No Abstract]   [Full Text] [Related]  

  • 2. Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months.
    Michael M; Antoniades M; Lemesiou E; Papaminas N; Melanthiou F
    Oncologist; 2009 Dec; 14(12):1198-200. PubMed ID: 19955186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Generalized erythema triggered by a rapid decrease of basophils in chronic myeloid leukemia treated with imatinib].
    Sugito M; Tsukada J; Higashi T; Ohta T; Matsuura A; Kubota A; Mizobe T; Mouri F; Morimoto H; Tanaka Y
    Rinsho Ketsueki; 2005 Nov; 46(11):1226-8. PubMed ID: 16440809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate.
    Garipidou V; Vakalopoulou S; Tziomalos K
    Oncologist; 2005; 10(6):457-8. PubMed ID: 15967839
    [No Abstract]   [Full Text] [Related]  

  • 5. Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities.
    Pawarode A; Sait SN; Nganga A; Coignet LJ; Barcos M; Baer MR
    Leuk Res; 2007 Nov; 31(11):1589-92. PubMed ID: 17391756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
    Khan KA; Junaid A; Siddiqui NS; Mukhtar K; Siddiqui S
    J Coll Physicians Surg Pak; 2008 Mar; 18(3):176-8. PubMed ID: 18460249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
    Breccia M; Alimena G
    Leuk Res; 2009 Nov; 33(11):1450-1. PubMed ID: 19615745
    [No Abstract]   [Full Text] [Related]  

  • 8. Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia.
    Galanopoulos A; Papadhimitriou SI; Kritikou-Griva E; Georgiakaki M; Anagnostopoulos NI
    Ann Hematol; 2009 Mar; 88(3):281-2. PubMed ID: 18726593
    [No Abstract]   [Full Text] [Related]  

  • 9. Challenging problems in advanced malignancy: Case 3. Imatinib mesylate-induced interstitial pneumonitis.
    Rosado MF; Donna E; Ahn YS
    J Clin Oncol; 2003 Aug; 21(16):3171-3. PubMed ID: 12915610
    [No Abstract]   [Full Text] [Related]  

  • 10. Ocular side effects in chronic myeloid leukemia patients treated with imatinib.
    Breccia M; Gentilini F; Cannella L; Latagliata R; Carmosino I; Frustaci A; Alimena G
    Leuk Res; 2008 Jul; 32(7):1022-5. PubMed ID: 18061664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia.
    Ayirookuzhi SJ; Ma L; Ramshesh P; Mills G
    Arch Dermatol; 2005 Mar; 141(3):368-70. PubMed ID: 15781678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy.
    Dib EG; Ifthikharuddin JJ; Scott GA; Partilo SR
    Leuk Res; 2005 Feb; 29(2):233-4. PubMed ID: 15607374
    [No Abstract]   [Full Text] [Related]  

  • 13. Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate.
    Anthony N; Shanks J; Terebelo H
    Leuk Res; 2010 Sep; 34(9):1250-1. PubMed ID: 20646761
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
    Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
    Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia.
    Chng WJ; Tan LH
    Leuk Res; 2005 Jun; 29(6):719-20. PubMed ID: 15863215
    [No Abstract]   [Full Text] [Related]  

  • 16. Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinib mesylate: a disease or a drug effect?
    Ram R; Gafter-Gvili A; Okon E; Pazgal I; Shpilberg O; Raanani P
    Acta Haematol; 2008; 119(2):104-7. PubMed ID: 18367829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac events in imatinib mesylate-treated chronic myeloid leukemia patients: A single institution experience.
    Breccia M; Cannella L; Frustaci A; Stefanizzi C; Levi A; Alimena G
    Leuk Res; 2008 May; 32(5):835-6. PubMed ID: 17905431
    [No Abstract]   [Full Text] [Related]  

  • 18. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
    Vernon MR; Pearson L; Atallah E
    J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation.
    Thierry A; Dreyfus B; Bridoux F; Abou Ayache R; Milin S; Guilhot F; Touchard G
    Nephrol Dial Transplant; 2007 Jun; 22(6):1791-2. PubMed ID: 17308316
    [No Abstract]   [Full Text] [Related]  

  • 20. Cutaneous Lichenoid dermatitis associated with imatinib mesylate.
    Chan CY; Browning J; Smith-Zagone MJ; Martinelli PT; Hsu S
    Dermatol Online J; 2007 May; 13(2):29. PubMed ID: 17498448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.